639090-54-3

Basic information

• Product Name: N-(4-sulfanylphenyl)cyclopropanecarboxamide
• Synonyms: N-(4-sulfanylphenyl)cyclopropanecarboxamide;Cyclopropanecarboxylic acid N-(4-sulfanylphenyl)amide;N-(4-mercaptophenyl)cyclopropanecarboxamide
• CAS NO: 639090-54-3
• Molecular Formula: C₁₀H₁₁NOS
• Molecular Weight: 193.27
• Mol File: 639090-54-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 408.6°C at 760 mmHg
• Flash Point: 200.9°C
• Appearance: /
• Density: 1.338
• Vapor Pressure: 6.93E-07mmHg at 25°C
• Refractive Index: 1.698
• Storage Temp.: 2-8°C
• PKA: 6.90±0.10(Predicted)
• CAS DataBase Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)
• EPA Substance Registry System: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)

Safety Data

• Hazardous Substances Data: 639090-54-3(Hazardous Substances Data)

Usage

General Description

N-(4-Sulfanylphenyl)cyclopropanecarboxamide is a chemical compound that belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aniline or a derivative thereof resulting from reaction of ammonia, where at least one hydrogen atom is replaced by an aryl group. The compound is very dense and has high boiling and melting points. It is typically presented as a white solid and is soluble in various solvents. This chemical is mainly used in the research and development stage of pharmaceutical and chemical industries. It's important to note that proper handling and storage are needed due to environmental and human health implications if ingested, inhaled, or comes into contact with skin.

InChI:InChI=1/C10H11NOS/c12-10(7-1-2-7)11-8-3-5-9(13)6-4-8/h3-7,13H,1-2H2,(H,11,12)

Upstream product

• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 1193-02-8 4-aminotiophenol 
• 1759-53-1 cyclopropanecarboxylic acid 

Downstream Products

• 639090-53-2 N-{4-[(4,6-dichloropyrimidin-2-yl)sulfanyl]phenyl}cyclopropane carboxamide 
• 883734-21-2 N-(4-(8-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropane carboxamide 
• 883734-23-4 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)-cyclopropane carboxamide 
• 883734-14-3 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide 
• 883737-15-3 N-(4-(2-ethyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide 
• 883734-19-8 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide 
• 1088937-37-4 (S)-N-(4-(4-(3-fluoropyrrolidin-1-yl)-6-(3-methyl-1H-pyrazol-5-ylamino)pyridin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1088937-35-2 (S)-N-(4-(4-(3-fluoropyrrolidin-1-yl)-6-(5-methylthiazol-2-ylamino)pyridin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 926647-18-9 N-(4-(6-chloropyrazin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1258423-29-8 N-(4-((4-((5-methyl-1H-pyrazol-3-yl)amino)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)thio)phenyl)cyclopropanecarboxamide 
• 1258423-74-3 C₂₄H₃₁N₉OS 
• 1258423-33-4 C₂₀H₂₁N₇OS 
• 1258223-00-5 N-(4-((4,6-dichloro-1,3,5-triazin-2-yl)thio)phenyl)cyclopropanecarboxamide 
• 1258423-31-2 C₁₉H₂₁N₇OS 

Relevant articles and documents

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

DRUG DISCOVERY METHODS

The present invention relates to drug discovery methods, particularly methods for assaying compounds for activity as Aurora kinase inhibitors. This invention also relates to a pharmacophore describing compounds that are able to promote a conformational ch